Skip to search formSkip to main contentSkip to account menu

natalizumab

Known as: Anti-VLA4, Anti-alpha4 integrin, Natalizumab [Chemical/Ingredient] 
A humanized recombinant IgG4 monoclonal antibody directed against the alpha4 subunit of the integrins alpha4beta1and alpha4beta7 with… 
National Institutes of Health

Related topics

Related topics

12 relations
15 ML natalizumab 20 MG/ML Injection [Tysabri]In BloodIntegrin alpha4NCIt Antineoplastic Agent Terminology

Narrower (3)

AntegrenTysabrimonoclonal antibody AN100226

Broader (1)

Immunologic Factors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
BACKGROUND Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of… 
Highly Cited
2006
Highly Cited
2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
BACKGROUND Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We… 
Highly Cited
2006
Highly Cited
2006
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
BACKGROUND Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many… 
Review
2006
Review
2006
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
BACKGROUND Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with… 
Highly Cited
2005
Highly Cited
2005
Natalizumab induction and maintenance therapy for Crohn's disease.
BACKGROUND Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into… 
Highly Cited
2005
Highly Cited
2005
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
We describe the clinical course of a patient with multiple sclerosis in whom progressive multifocal leukoencephalopathy (PML), an… 
Highly Cited
2005
Highly Cited
2005
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
The prior diagnosis of fatal astrocytoma in a 60-year-old man with Crohn's disease treated with natalizumab, a monoclonal… 
Highly Cited
2005
Highly Cited
2005
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
A 46-year-old woman with relapsing-remitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PML) after… 
Highly Cited
2003
Highly Cited
2003
A controlled trial of natalizumab for relapsing multiple sclerosis.
BACKGROUND In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving… 
Highly Cited
2003
Highly Cited
2003
Natalizumab for active Crohn's disease.
BACKGROUND In chronic inflammatory conditions such as Crohn's disease, the migration of leukocytes from the circulation into the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)